Results 91 to 100 of about 53,199 (230)

Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. [PDF]

, 2015
Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for ...
Pabst, Thomas, Mueller, Beatrice U, Leibundgut, Kurt, Seipel, Katja, Keller, Sandra, Mansouri Taleghani, Behrouz, Novak, Urban   +6 more
core   +3 more sources

Brain calcification‐associated JAM2 pathogenic mutations impair JAM2–JAM3 tight junction structure and the blood–brain barrier integrity

Brain Pathology, EarlyView.
Pathogenic JAM2 mutations disrupt the JAM2–JAM3 heterodimer structure and tight junction integrity, leading to blood–brain barrier breakdown. Consequently, Jam2‐deficient mice develop prominent midbrain calcification and significant motor impairments, identifying the JAM2–JAM3 interaction as a vital target for primary brain calcification therapeutics ...
Dehao Yang, Lebo Wang, Chenxin Ying, Yihua Shi, Yuru Guo, Haotian Wang, Xinhui Chen, Yaoting Wang, Xinchen Wang, Fan Zhang, Xiaosheng Zheng, Yiling Chen, Haoyu Wang, Zhiru Lin, Jiaxiang Li, Haibin Xia, Jiawen Chen, Feng Fu, Bo Wang, Sheng Wu, Ping Wang, Fei Xie, Zhidong Cen, Zhiping Wang, Wei Luo   +24 more
wiley   +1 more source

Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment

Scientific Reports
Neuroblastoma (NB) is the most common pediatric tumor and is currently treated by several types of therapies including chemotherapies, such as bortezomib treatment.
Kévin Berthenet, Eliézer Aïmontché, Sara El Mrini, Johan Brière, Nathalie Pion, Isabelle Iacono, Stéphanie Brejon, Karine Monier, Frédéric Catez, Gabriel Ichim, Valérie Combaret, Hichem C. Mertani, Jean-Jacques Diaz, Marie Alexandra Albaret   +13 more
doaj   +1 more source

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

Haematologica, 2015
We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone ...
Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt   +22 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Update on the optimal use of bortezomib in the treatment of multiple myeloma

, 2017
Meera Mohan, Aasiya Matin, Faith E Davies Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA Abstract: The proteasome inhibitor (PI) “bortezomib” has now been in routine clinical practice for ...
Mohan M, Davies FE, Matin A
core  

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Bortezomib induces autophagy in HCC.

, 2013
A, dose-dependent effects of bortezomib-induced autophagy. HCC cells were treated with bortezomib at the indicated concentrations for 24 hours. Cell lysates were prepared for immunoblotting of microtubule-associated protein 1 light chain 3 (LC3). B, time-
Chung-Wai Shiau (285430), Chun-Yu Liu (79948), Ann-Lii Cheng (285432), Duen-Ren Hou (285426), Kuen-Feng Chen (285433), Hui-Chuan Yu (285424), Chen-Si Lin (285428)   +6 more
core   +1 more source